Top

Published in:

01-02-2016 | Epidemiology

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers

Authors: Ines Vaz-Luis, Melissa E. Hughes, Angel Cronin, Hope S. Rugo, Stephen B. Edge, Beverly Moy, Richard L. Theriault, Michael J. Hassett, Eric P. Winer, Nancy U. Lin

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Abstract

Breast-conserving surgery (BCS) provides equivalent survival outcomes to unilateral mastectomy. There is no survival advantage to bilateral mastectomy in average risk breast cancer. Among a cohort of breast cancer patients expected to be candidates for BCS, we examined choice of surgery and factors associated with it. A prospective cohort study of unilateral clinical Stage I breast cancer patients treated at National Comprehensive Cancer Network centers from 2000 to 2009 was performed. The proportion of patients who initially underwent mastectomy versus BCS and time to definitive surgery and chemotherapy were examined. Of 10,249 patients, 23 % underwent mastectomy as an initial surgery. No decline in the use of mastectomy as initial surgery was found. There was significant institutional variation, with rates of initial mastectomy ranging from 14 to 30 % (adjusted odds ratio: 0.42–1.38). Tumor characteristics were associated with surgical option, but with small absolute differences. Of those who received initial mastectomy, 22 % had bilateral mastectomy, with an increase over time (2000:13 % vs. 2009:30 %) and substantial institutional variation (11–34 %). Women treated with initial mastectomy had longer median times from diagnosis to complete definitive surgery (6 vs. 4 weeks) and to start of adjuvant chemotherapy (12 vs. 11 weeks). Among Stage I breast cancer, the overall use of mastectomy did not change significantly over 10 years; however, an increasing proportion of women with unilateral cancer had bilateral mastectomy, and there was wide variation in type of surgery by institution. Further studies to assess reasons for the observed wide variation are warranted.

Available only for authorised users

Blichert-Toft M, Rose C, Andersen JA et al (1992) Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 11:19–25PubMed

Lichter AS, Lippman ME, Danforth DN Jr et al (1992) Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol 10:976–983PubMed

Sarrazin D, Le MG, Arriagada R et al (1989) Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 14:177–184CrossRefPubMed

Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1232CrossRefPubMed

van Dongen JA, Voogd AC, Fentiman IS et al (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 92:1143–1150CrossRefPubMed

Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106CrossRefPubMed

Kurian AW, Lichtensztajn DY, Keegan TH et al (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 312:902–914CrossRefPubMed

Du X, Freeman DH Jr, Syblik DA (2000) What drove changes in the use of breast conserving surgery since the early 1980s? The role of the clinical trial, celebrity action and an NIH consensus statement. Breast Cancer Res Treat 62:71–79CrossRefPubMed

Lazovich D, Solomon CC, Thomas DB et al (1999) Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer 86:628–637CrossRefPubMed

10.

Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088PubMedCentralCrossRefPubMed

11.

Gomez SL, Lichtensztajn D, Kurian AW et al (2010) Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol 28:e155–e157 (author reply e158) CrossRefPubMed

12.

Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed

13.

McGuire KP, Santillan AA, Kaur P et al (2009) Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 16:2682–2690CrossRefPubMed

14.

Guadagnoli E, Weeks JC, Shapiro CL et al (1998) Use of breast-conserving surgery for treatment of stage I and stage II breast cancer. J Clin Oncol 16:101–106PubMed

15.

Habermann EB, Abbott A, Parsons HM et al (2010) Are mastectomy rates really increasing in the United States? J Clin Oncol 28:3437–3441CrossRefPubMed

16.

Nattinger AB, Gottlieb MS, Veum J et al (1992) Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 326:1102–1107CrossRefPubMed

17.

Morrow M, White J, Moughan J et al (2001) Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 19:2254–2262PubMed

18.

Gregorio DI, Kulldorff M, Barry L et al (2001) Geographical differences in primary therapy for early-stage breast cancer. Ann Surg Oncol 8:844–849CrossRefPubMed

19.

Greenberg CC, Lipsitz SR, Hughes ME et al (2011) Institutional variation in the surgical treatment of breast cancer: a study of the NCCN. Ann Surg 254:339–345PubMedCentralCrossRefPubMed

20.

Kummerow KL, Du L, Penson DF et al (2015) Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 150:9–16CrossRefPubMed

21.

Lizarraga I, Schroeder MC, Weigel RJ, Thomas A (2015) Surgical management of breast cancer in 2010–2011 SEER registries by hormone and HER2 receptor status. Ann Surg Oncol 22:566–572CrossRefPubMed

22.

Showalter SL, Grover S, Sharma S et al (2013) Factors influencing surgical and adjuvant therapy in stage I breast cancer: a SEER 18 database analysis. Ann Surg Oncol 20:1287–1294CrossRefPubMed

23.

Weeks JC (1997) Outcomes assessment in the NCCN. Oncol (Williston Park) 11:137–140

24.

Punglia RS, Hughes ME, Edge SB et al (2008) Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network. Int J Radiat Oncol Biol Phys 72:1434–1440PubMedCentralCrossRefPubMed

25.

Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258–1267CrossRefPubMed

26.

Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRefPubMed

27.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed

28.

Katz JN, Chang LC, Sangha O et al (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73–84CrossRefPubMed

29.

Morrow M (2005) Limiting breast surgery to the proper minimum. Breast 14:523–526CrossRefPubMed

30.

Farrow DC, Hunt WC, Samet JM (1992) Geographic variation in the treatment of localized breast cancer. N Engl J Med 326:1097–1101CrossRefPubMed

31.

Tuttle TM, Rueth NM, Abbott A, Virnig BA (2012) United States trends in the surgical treatment of primary breast cancer. World J Surg 36:1475–1479CrossRefPubMed

32.

Chagpar AB, Studts JL, Scoggins CR et al (2006) Factors associated with surgical options for breast carcinoma. Cancer 106:1462–1466CrossRefPubMed

33.

Rosenberg SM, Tracy MS, Meyer ME et al (2013) Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med 159:373–381PubMedCentralCrossRefPubMed

34.

Vandergrift JL, Niland JC, Theriault RL et al (2013) Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst 105:104–112PubMedCentralCrossRefPubMed

Title: Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers
Authors: Ines Vaz-Luis
Melissa E. Hughes
Angel Cronin
Hope S. Rugo
Stephen B. Edge
Beverly Moy
Richard L. Theriault
Michael J. Hassett
Eric P. Winer
Nancy U. Lin
Publication date: 01-02-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3707-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies

Healthy dietary patterns and risk of breast cancer by molecular subtype

Associations of sex steroid hormones with mortality in women with breast cancer

Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)

Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor

The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer